UNSPSC 51192306: Calcium/chloride/gluconate/magnesium/potassium/sodium/sulfate

This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class TN490. This VA Drug Class (TN490) classifies this compound as belonging to the group ELECTROLYTES/MINERALS, COMBINATIONS.

UNSPSC 51192306 Calcium/chloride/gluconate/magnesium/potassium/sodium/sulfate (Commodity) covers chemical supply products used in municipal water treatment and public health operations, though recent state and local opportunities show narrower, more specialized procurement — primarily sodium bisulfite for water pollution control and generic pharmaceuticals with specific electrolyte or mineral components distributed through cooperative purchasing arrangements. State and local governments soliciting under this code span municipal water utilities, state health departments, and multistate cooperative purchasing alliances. The City of Meriden, Connecticut and the Minnesota Department of Administration (via the Minnesota Multistate Cooperative Purchasing Alliance, or MMCAP) represent the jurisdictional mix; both are active repeat buyers in this chemical and pharmaceutical supply space, though they procure distinct product types under the same code classification.

Recent activity centers on Connecticut and Minnesota. The City of Meriden issued an IFB for sodium bisulfite chemical supply for its Water Pollution Control Facility (solicitation B027-15, due July 29, 2026), requiring General Liability insurance of $1,000,000 to $2,000,000 and performance and payment bonds. MMCAP, administered by Minnesota's Office of State Procurement, issued an RFP (S1070000015802, due March 26, 2026) to establish multi-award contracts for generic pharmaceuticals and OTC products across participating state and local government facilities in Minnesota and Oregon, with contracts effective July 1, 2026; vendors must work through three authorized wholesalers (AmerisourceBergen Drug Corporation, Cardinal Health, and Morris & Dickson Co., LLC), comply with cGMP and DSCSA standards, and maintain commercial general liability coverage of $5,000,000 per occurrence. Pricing evaluation in the MMCAP RFP weighted price competitiveness at 75 percent.